Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | STS | P08842 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027932 | 0.95 | HSD17B3 (0.66) | HSD17B3HTR7STSL3MBTL1ALDH1A1 | |
| SCHEMBL6839650 | 0.93 | HSD17B3 (0.67) | HSD17B3HTR7STSL3MBTL1 | |
| SCHEMBL3844202 | 0.93 | HSD17B3 (0.67) | HSD17B3HTR7STSL3MBTL1 | |
| SCHEMBL9506499 | 0.93 | HSD17B3 (0.67) | HSD17B3HTR7STSL3MBTL1 | |
| SCHEMBL6579588 | 0.89 | HSD17B3 (0.62) | HSD17B3HTR7STSL3MBTL1ALDH1A1 | |
| SCHEMBL14522305 | 0.86 | HSD17B3 (0.83) | HSD17B3HTR7STSL3MBTL1NPC1 | |
| SCHEMBL2903307 | 0.86 | HSD17B3 (0.58) | HSD17B3 | |
| SCHEMBL8384454 | 0.84 | HSD17B3 (0.62) | HSD17B3HTR7STSL3MBTL1NPC1 | |
| SCHEMBL28033085 | 0.81 | ALDH1A1 (0.48) | HSD17B3HTR7L3MBTL1ALDH1A1NPC1 | |
| SCHEMBL6577194 | 0.80 | ALDH1A1 (0.56) | HSD17B3L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0856007-B1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| EP-0856007-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997014716-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | HSD17B3 943/4885HTR7 3098/4885STS 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.